newsfilter
← Latest News
Earnings Call Transcripts·

Oric Pharmaceuticals, Inc. Jefferies Global Healthcare Conference in London - ORIC PHARMACEUTICALS INC

  • Financial Performance:

    • Cash Position: Ended Q3 2025 with $345 million in cash and investments.
    • Runway: Provides a fully burdened cash runway extending into the second half of 2028, covering costs for ongoing Phase 3 trials and anticipated future Phase 3 launches.
    • Profitability/Margins: No revenue or profit margins reported as the company is in late-stage clinical development; the focus remains on drug development costs and trial execution.
    • Debt: No mention of debt in the transcript; the company appears to be equity-funded with a strong liquidity position.
  • Guidance and Future Outlook:

    • Rinzimetastat (Prostate): Top-line data expected for the Phase 3 "Himalayas 1" study in the first half of 2026 (enrollment targeting 16 months, study designed for faster readout with 95% power for 0.66 hazard ratio).
    • Enozertinib (Lung): Phase 3 trials ("Redwood 1") for EGFR atypical and Exon 20 mutations planned to initiate in 2026, with potential to start earlier if data supports.
    • Market Opportunity: Targeting two post-AR inhibitor populations (post-abiraterone and post-AR inhibitor) representing a $3.5 billion US market each; potential to expand into castration-sensitive prostate cancer (CSBC) for a $10 billion opportunity.
    • Development Path: Plans to accelerate development into earlier lines of therapy (CSBC) if competitor data (Pfizer's Mevrometastat) validates the mechanism's efficacy and safety.
  • Business Segments and Product Lines:

    • Rinzimetastat (PRC2 Inhibitor): Oral PRC2 EED inhibitor developed in combination with darolutamide for prostate cancer.
      • Clinical Data: Demonstrates 60% 10-month landmark PFS in both post-abiraterone and post-AR inhibitor cohorts, comparable to Pfizer's data but with a significantly cleaner safety profile (reduced GI and hematologic toxicity).
      • Differentiation: 20-hour half-life (vs. 4-hour for Pfizer's drug), lower dose (400mg vs. 1.8g daily), no CYP autoinduction, and minimal food effect.
    • Enozertinib (EGFR Inhibitor): Oral drug targeting EGFR atypical mutations and Exon 20 mutations in lung cancer.
      • Clinical Data: 84% overall response rate (ORR) and 70% intracranial response rate (IRR) in a heavily pre-treated population with brain metastases; 88% 6-month landmark PFS.
      • Differentiation: Superior CNS penetration compared to non-brain-penetrant competitors; minimal EGFR wild-type related toxicity (e.g., liver enzyme elevations, anemia).
  • Market and Competitive Landscape:

    • Prostate Cancer Competition: Pfizer's Mevrometastat is the primary comparator; OREC expects top-line data in Q1 2026. J&J's RIPTAC (6143) showed early promise but requires further durability and safety data; no combination with AR inhibitors possible due to binding domain overlap.
    • Lung Cancer Competition: Competitors include Amivantamab (J&J), Black Diamond, and Aravant; OREC differentiates via CNS efficacy and a safety profile lacking wild-type EGFR toxicities.
    • Market Trends: Shift toward brain-penetrant therapies for lung cancer and combination therapies targeting epigenetic modifiers in prostate cancer; safety profile is the key driver for physician adoption (similar to the trajectory of apalutamide/darolutamide in the AR inhibitor space).
  • Risks and Challenges:

    • Clinical Trial Readouts: Potential for Pfizer's Mevrometastat to result in a "near miss" (statistically significant but modest efficacy or safety issues) due to food effects, drug-drug interactions (CYP induction), or toxicities leading to dose reductions.
    • Competitor Uncertainty: J&J's RIPTAC requires more data on durability and safety before OREC can consider combination strategies.
    • Trial Execution: Maintaining enrollment and site activation for the 600-patient Himalayas 1 study; managing variability in physician choice control arms (AR switch vs. chemotherapy).
    • Regulatory/Operational: Ensuring the "less pretreated" population in Phase 3 accurately reflects the efficacy seen in more heavily pre-treated Phase 2 cohorts.
  • Management Commentary and Tone:

    • Tone: Highly confident and optimistic; management emphasizes the "dogma" in lung cancer favoring CNS-penetrant drugs and the clear safety differentiation of their prostate program.
    • Confidence: Expresses near certainty that Pfizer will not result in a "big miss," while highlighting that any "near miss" scenarios (food effects, DDIs) do not apply to OREC's assets due to their superior pharmacokinetics.
    • Strategic Focus: Aggressive pursuit of faster development timelines to capitalize on the validated PRC2 and CNS-penetrant mechanisms.
  • Analyst Questions and Answers:

    • Q: How does Rinzimetastat differ pharmacologically from Pfizer's Mevrometastat?
      • A: Rinzimetastat targets the EED subunit (allosteric inhibition) with a 20-hour half-life and no CYP autoinduction, allowing lower dosing (400mg vs. 1.8g) and a cleaner safety profile compared to Pfizer's EZH2-targeted, shorter half-life drug.
    • Q: What does the delay in Pfizer's top-line data imply?
      • A: Likely indicates fewer events (treatment arm doing well), a skew in the control arm toward less active AR switches, or high censoring; statistically, a "big miss" is ruled out.
    • Q: What would constitute a "near miss" for OREC if Pfizer misses?
      • A: A modest hazard ratio or efficacy signal that is statistically significant but not "game-changing"; however, OREC believes their differentiation prevents direct negative read-through from Pfizer's potential near miss.
    • Q: How do you view J&J's RIPTAC data?
      • A: Impressive early data (PSA 50/90) but requires longer follow-up on durability and safety (liver/kidney tox) before potential combination strategies can be considered.
  • Other Key Points:

    • Trial Design: OREC's Phase 3 "Himalayas 1" mirrors Pfizer's design (600 patients, radiographic PFS primary endpoint) to allow direct side-by-side comparison of efficacy and safety.
    • Safety Profile: OREC highlights that their combination with darolutamide avoids CYP induction issues seen with enzalutamide (used by Pfizer), reducing variability in drug exposure.
    • Funding Status: The $345 million cash position is sufficient to fund the company past the critical data readouts for both major programs, eliminating near-term financing risk.
Company
ORIC PHARMACEUTICALS INC
Keywords
ORIC PHARMACEUTICALS INC